Cara Therapeutics (CARA) Misses Q1 EPS by 16c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts CARA Hot Sheet
Join SI Premium – FREE
Cara Therapeutics (NASDAQ: CARA) reported Q1 EPS of ($0.56), $0.16 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $2.14 million versus the consensus estimate of $1.69 million.
Financial Guidance
Cara expects that our current unrestricted cash and cash equivalents and available-for-sale marketable securities will be sufficient to fund our currently anticipated operating plan into 2026. Our current operating plan assumes certain costs related to our planned pivotal trials in NP.
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura flags this tech pocket as 'portfolio shelter' from AI spending pressure
- Lumentum Holdings (LITE) Tops Q1 EPS by 36c ; Offers Guidance
- Lightbridge (LTBR) Misses Q3 EPS by 23c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
